The challenge of administering anti-tuberculosis treatment in infants and pre-school children. pTBred Magistral Project

Pérez, Roi Piñeiro; García, Begoña Santiago; Fernández-Llamazares, Cecilia M.; Baquero-Artigao, Fernando; Julian, Antoni Noguera; Peña, María José

doi:10.1016/j.anpede.2015.07.038

Cited by 1 publication

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The justification for this health policy gap was 2-fold; firstly, young children were considered a lightly infected population and therefore thought to be at low risk for schistosomiasis-associated morbidity; secondly, there was no child-friendly formulation for oral treatment that would decrease the risk of choking. Crushing tablets to treat younger children was not considered practical for national programmes, although this approach is widely performed for pill treatment of other diseases such as tuberculosis (Pineiro Perez et al 2016). In essence, the under-fives were not seriously considered at risk and they were deemed too difficult and unsafe to treat, so they were excluded.…”

Section: Early Years (<5 Years Of Age)mentioning

confidence: 99%

One hundred years of neglect in paediatric schistosomiasis

et al. 2017

View full text Add to dashboard Cite

Early in the history of schistosomiasis research, children under 5 years of age were known to be infected. Although this problem was recognized over 100 years ago, insufficient action has been taken to address this issue. Under current policy, such infected children only receive their first antiparasitic treatment (praziquantel - PZQ) upon entry into primary school as current mass drug administration programmes typically target school-aged children. For many infected children, they will wait up to 6 years before receiving their first medication and significant schistosomiasis-related morbidity may have already established. This inequity would not be accepted for other diseases. To unveil some of the reasons behind this neglect, it is paramount to understand the intricate historical relationship between schistosomiasis and British Imperial medicine, to underline its lasting influence on today's public health priorities. This review presents a perspective on the historical neglect of paediatric schistosomiasis, focusing on important gaps that persist from the early days after discovery of this parasite. Looking to end this inequity, we address several issues that need to be overcome to move forward towards the lasting success of schistosomiasis control and elimination efforts.

show abstract

Section: Early Years (<5 Years Of Age)mentioning

confidence: 99%